Expert Opinion on Therapeutic Targets

Aims & Scope

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development.

Articles in this journal focus on the molecular level and early preclinical studies.

Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.4
2024	4.60

SJR (SCImago Journal Rank)

Year	Value
2024	1.255

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	113

Journal Rank

Year	Value
2024	3276

Journal Citation Indicator

Year	Value
2024	1115

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

  Citation: 825

  Authors: Libero, Scott M, Adel K

• Targeting the EGFR signaling pathway in cancer therapy

  Citation: 759

  Authors: Parthasarathy, Moorthy P, Dhanya, Maneesh, Apar K, Surinder K

• The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

  Citation: 565

  Authors: Antonella, Monica R, Amelia, Maria, Nicola

• The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy

  Citation: 333

  Authors: Yong, Lang, Wenjie, Shanling

• Cathepsin B as a cancer target

  Citation: 326

  Authors: Christopher S, Jasti S

• Targeting selectins and selectin ligands in inflammation and cancer

  Citation: 324

  Authors: Steven R, Jacyln D, Leyla, Charles J

• Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase

  Citation: 313

  Authors: Usune, Ana Laura, Javier, J Alfredo, Fermín I

• The IL-6/sIL-6R complex as a novel target for therapeutic approaches

  Citation: 301

  Authors: Stefan, Georg H, Jürgen, Joachim, Dirk

• Targeting CCL5 in inflammation

  Citation: 293

  Authors: Rafael Elias, Rodrigo, Remo Castro, Mauro Martins

• The paraventricular nucleus of the hypothalamus – a potential target for integrative treatment of autonomic dysfunction

  Citation: 276

  Authors: Alastair V, Kevin J, Willis K

---